Pain and Opioid Management in Older Adults (RISE-OK)
Primary Purpose
Pain, Chronic, Opioid Use Disorder
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dissemination and Implementation Research
Sponsored by
About this trial
This is an interventional health services research trial for Pain, Chronic focused on measuring Pain Management, Opioid Use Disorder in Older Adults, Implementation Science, Primary Care Practice Improvement
Eligibility Criteria
Inclusion Criteria:
- For the Practice: Deliver primary care services to older adults. Be located in Oklahoma. Be willing to complete a pre- and post-practice characteristic and building blocks of primary care survey. Use an electronic health record.
- For Practice Clinicians: Be an MD, DO, PA, or APRN licensed to practice in Oklahoma. Be willing to complete a pre- and post- practice member survey. Be willing to work with the OPHIC external support personnel to use the performance measures.
- For Practice Staff: Be employed by the practice. Be willing to complete a pre- and post- practice member survey. Be willing to work with the OPHIC external support personnel to use performance measures to optimize pain management approaches in older adults.
- For Practice Patients: Be chronic pain patients aged 60 or older, or may be younger, but vulnerable due to disability, significant functional limitation or social deprivation. Be willing to complete PROMIS-29 surveys, participate in RISE-OK Project activities, and provide feedback on the RISE-OK program.
Exclusion Criteria:
- Practices: Does not provide primary care. Provides only urgent care and does not provide continuity of care or long-term follow-up care. Does not use an electronic health record.
- Clinicians: Do not provide primary care with continuity and chronic care follow-up. Planning to leave practice within the next 12 months, including if the clinician is planning to retire within the next 12 months.
- Practice Staff: Under 18 years of age.
- Patients: Not older adult chronic pain patients.
Sites / Locations
- Oklahoma Clinical and Translational Science InstituteRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Primary Care Practices
Arm Description
Dissemination and Implementation Research
Outcomes
Primary Outcome Measures
Health-Related Quality of Life and Functioning: Physical Health Summary Score
Change in Patient-Reported Outcomes Measurement Information System Survey (PROMIS-29) Physical Health Summary Score
Health-Related Quality of Life and Functioning: Mental Health Summary Score
Change in Patient-Reported Outcomes Measurement Information System Survey (PROMIS-29) Mental Health Summary Score
Morphine Milligram Equivalent (MME)
Change in mean opioid Morphine Milligram Equivalent (MMEs) at the practice level
Secondary Outcome Measures
Self-Efficacy
Arthritis Self-Efficacy Scale (ASES) Score. The Arthritis Self-Efficacy Scale has 20 items in 3 subscales: self-efficacy for managing pain (PSE), 5 items; self-efficacy for physical function (FSE), 9 items; and self-efficacy for controlling other systems (OSE), 6 items. Items are rated on a 1 (very uncertain) to 10 (very certain) rating scale. Higher scores indicate greater confidence or self-efficacy.
Self-Efficacy
Arthritis Self-Efficacy Scale (ASES) Score. The Arthritis Self-Efficacy Scale has 20 items in 3 subscales: self-efficacy for managing pain (PSE), 5 items; self-efficacy for physical function (FSE), 9 items; and self-efficacy for controlling other systems (OSE), 6 items. Items are rated on a 1 (very uncertain) to 10 (very certain) rating scale. Higher scores indicate greater confidence or self-efficacy.
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Pain-Related Goal Attainment
Summary of 3-point Pain-Related Goal Attainment Scaling. Patients will rate their Pain-Related Goal Attainment using a 3-category response scale (somewhat less than expected (-1), expected goal achievement (0), and somewhat better than expected (+1).
Pain-Related Goal Attainment
Summary of 3-point Pain-Related Goal Attainment Scaling. Patients will rate their Pain-Related Goal Attainment using a 3-category response scale (somewhat less than expected (-1), expected goal achievement (0), and somewhat better than expected (+1).
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Chronic Opioid Therapy Statistics: Eligible Patients
Number of patients 60+ years of age on chronic opioids
Chronic Opioid Therapy Statistics: Eligible Patients
Number of patients 60+ years of age on chronic opioids
Chronic Opioid Therapy Statistics: Visit Addressing Pain Management
% of patients on chronic opioids that were seen at a visit addressing pain management in the 6 months prior to Baseline.
Chronic Opioid Therapy Statistics: Visit Addressing Pain Management
% of patients on chronic opioids that were seen at a visit addressing pain management in the 6 months prior to Month 17 of the study.
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
% of patients on chronic opioids with a chronic pain diagnosis
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
% of patients on chronic opioids with a chronic pain diagnosis
Chronic Opioid Therapy Statistics: High Risk Patients
% of patients on chronic opioids with MME>50 and benzo
Chronic Opioid Therapy Statistics: High Risk Patients
% of patients on chronic opioids with MME>50 and benzo
Full Information
NCT ID
NCT05037682
First Posted
July 12, 2021
Last Updated
November 21, 2022
Sponsor
University of Oklahoma
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
1. Study Identification
Unique Protocol Identification Number
NCT05037682
Brief Title
Pain and Opioid Management in Older Adults
Acronym
RISE-OK
Official Title
Addressing Opioid Use Disorder in the Elderly Through Primary Care Innovation: Pain and Opioid Management in Older Adults
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 30, 2020 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
September 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oklahoma
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The extent and depth of the ongoing opioid crisis are well known and many interventions are under way in the United States and other countries to alleviate its devastating impact on individuals and the society. To address specific challenges of pain and opioid management (POM) in older and vulnerable adults, the investigators will design and implement a multi-faceted, person-centered, and scalable opioid use disorder (OUD) management program in Oklahoma primary care practices. The investigators expect that the rigorously designed and evidence-based program will establish and disseminate innovative solutions for pain and opioid management in high-risk, older and vulnerable populations living with chronic pain. The proposed initiative will help primary care practices optimize pain management approaches in older adults through an integrated and trans-disciplinary application of innovations in multi-modal pain management, pain mechanism-based pharmacotherapy, patient goal-oriented care, implementation science, evidence-based quality improvement methodology, and community-engaged design.
Detailed Description
The project's specific aims are:
Building upon existing guidelines and tools that the investigators' collaborative has developed and implemented for pain and opioid management (POM), refine and tailor care processes, implementation support strategies, and shared decision support resources to the specific needs of older adults in primary care settings, using a systematic approach, including:
Conduct a rapid, iterative process, through which a diverse healthcare professional expert panel adapts and enhances existing POM approaches and tools to older adult patients (POMOA);
Implement a subsequent formative process, through which a patient and caregiver community advisory board ensures that the tailored POM approach and resources are acceptable, usable, context-sensitive and value-added for older adults and their caregivers; and
Assemble tailored resources to create a POMOA Toolkit from which primary care practices can select sets of resources based on their specific needs, guided by academic detailers and practice facilitators.
Over a 2-year period, help a minimum of 36 Oklahoma primary care practices implement a person-centered, goal-oriented, and community-linked approach to pain management, tailored to older adults. The implementation approach will include the following:
Using benchmarking and performance feedback, academic detailing, practice facilitation, and technology support, help practices integrate the tailored POMOA approach and resources into their workflows, focusing on improving patient functioning, self-efficacy, and the optimization of pain management; and
Through ongoing observation and analysis, identify facilitators and barriers to program implementation to accelerate convergence on effective and replicable methods.
Conduct a multi-dimensional and comprehensive evaluation of the impact of the RISE-OK program, including the measurement of the following outcomes:
Patient-Centered Outcomes: Patient health-related quality of life and functioning (PROMIS-29), self- efficacy for pain management using a modified Arthritis Self-Efficacy scale (ASES), pain interference (Pain-Enjoyment-General Activity), and functional goal attainment (Goal Attainment Scaling);
Care Quality Outcomes: Patient utilization of opioid medications (morphine milligram equivalents) and alternative therapies in older adults, change in prescribing patterns, and diversification of pharmacological and non-pharmacological pain therapies;
Care Process Outcomes: Impact of the program on practice-level care process outcomes (chronic opioid therapy registry use; systematic chronic opioid therapy visits; pain impact/interference measurement, pain management and risk/benefit conversations; naloxone prescription; tapering practices; patient/caregiver education; shared decision-making; referrals/community service linkages; medication assisted therapy utilization); and
Qualitative Outcomes: Healthcare professional, health system leadership, patient, and caregiver perceptions of the utility, effectiveness and generalizability of the RISE-OK program, explored via semi-structured interviews, exit surveys, and in-depth program implementation process observations.
Disseminate innovative approaches and products developed by the RISE-OK project in several ways:
Community-based dissemination (community-based and professional health organizations);
Academic dissemination (presentations, workshops, papers, Agency for Healthcare Research and Quality's communication professionals); Web-based and social networking-based dissemination (e.g., Research-to-Practice Exchange).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Chronic, Opioid Use Disorder
Keywords
Pain Management, Opioid Use Disorder in Older Adults, Implementation Science, Primary Care Practice Improvement
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Dissemination and Implementation Research (D&I): Involves assisting primary care practices to address pain and opioid management in older adults. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
Masking
None (Open Label)
Allocation
N/A
Enrollment
1035 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Primary Care Practices
Arm Type
Other
Arm Description
Dissemination and Implementation Research
Intervention Type
Other
Intervention Name(s)
Dissemination and Implementation Research
Intervention Description
The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
Primary Outcome Measure Information:
Title
Health-Related Quality of Life and Functioning: Physical Health Summary Score
Description
Change in Patient-Reported Outcomes Measurement Information System Survey (PROMIS-29) Physical Health Summary Score
Time Frame
Baseline to 17 months
Title
Health-Related Quality of Life and Functioning: Mental Health Summary Score
Description
Change in Patient-Reported Outcomes Measurement Information System Survey (PROMIS-29) Mental Health Summary Score
Time Frame
Baseline to 17 months
Title
Morphine Milligram Equivalent (MME)
Description
Change in mean opioid Morphine Milligram Equivalent (MMEs) at the practice level
Time Frame
Baseline to 17 months
Secondary Outcome Measure Information:
Title
Self-Efficacy
Description
Arthritis Self-Efficacy Scale (ASES) Score. The Arthritis Self-Efficacy Scale has 20 items in 3 subscales: self-efficacy for managing pain (PSE), 5 items; self-efficacy for physical function (FSE), 9 items; and self-efficacy for controlling other systems (OSE), 6 items. Items are rated on a 1 (very uncertain) to 10 (very certain) rating scale. Higher scores indicate greater confidence or self-efficacy.
Time Frame
Baseline
Title
Self-Efficacy
Description
Arthritis Self-Efficacy Scale (ASES) Score. The Arthritis Self-Efficacy Scale has 20 items in 3 subscales: self-efficacy for managing pain (PSE), 5 items; self-efficacy for physical function (FSE), 9 items; and self-efficacy for controlling other systems (OSE), 6 items. Items are rated on a 1 (very uncertain) to 10 (very certain) rating scale. Higher scores indicate greater confidence or self-efficacy.
Time Frame
17 months
Title
Pain-Function Interference
Description
3-item Pain-Enjoyment-General Activity (PEG) score
Time Frame
Baseline
Title
Pain-Function Interference
Description
3-item Pain-Enjoyment-General Activity (PEG) score
Time Frame
Month 5
Title
Pain-Function Interference
Description
3-item Pain-Enjoyment-General Activity (PEG) score
Time Frame
Month 8
Title
Pain-Function Interference
Description
3-item Pain-Enjoyment-General Activity (PEG) score
Time Frame
Month 12
Title
Pain-Function Interference
Description
3-item Pain-Enjoyment-General Activity (PEG) score
Time Frame
Month 17
Title
Pain-Related Goal Attainment
Description
Summary of 3-point Pain-Related Goal Attainment Scaling. Patients will rate their Pain-Related Goal Attainment using a 3-category response scale (somewhat less than expected (-1), expected goal achievement (0), and somewhat better than expected (+1).
Time Frame
Baseline
Title
Pain-Related Goal Attainment
Description
Summary of 3-point Pain-Related Goal Attainment Scaling. Patients will rate their Pain-Related Goal Attainment using a 3-category response scale (somewhat less than expected (-1), expected goal achievement (0), and somewhat better than expected (+1).
Time Frame
Month 17
Title
Polypharmacy Risk
Description
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time Frame
Baseline
Title
Polypharmacy Risk
Description
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time Frame
Month 5
Title
Polypharmacy Risk
Description
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time Frame
Month 8
Title
Polypharmacy Risk
Description
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time Frame
Month 12
Title
Polypharmacy Risk
Description
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time Frame
Month 17
Title
Diversification of Pain Therapy
Description
Number (and Type) of pharmacological and non-pharmacological treatment types
Time Frame
Baseline
Title
Diversification of Pain Therapy
Description
Number (and Type) of pharmacological and non-pharmacological treatment types
Time Frame
Month 5
Title
Diversification of Pain Therapy
Description
Number (and Type) of pharmacological and non-pharmacological treatment types
Time Frame
Month 8
Title
Diversification of Pain Therapy
Description
Number (and Type) of pharmacological and non-pharmacological treatment types
Time Frame
Month 12
Title
Diversification of Pain Therapy
Description
Number (and Type) of pharmacological and non-pharmacological treatment types
Time Frame
Month 17
Title
Chronic Opioid Therapy Statistics: Eligible Patients
Description
Number of patients 60+ years of age on chronic opioids
Time Frame
Baseline
Title
Chronic Opioid Therapy Statistics: Eligible Patients
Description
Number of patients 60+ years of age on chronic opioids
Time Frame
Month 17
Title
Chronic Opioid Therapy Statistics: Visit Addressing Pain Management
Description
% of patients on chronic opioids that were seen at a visit addressing pain management in the 6 months prior to Baseline.
Time Frame
Baseline
Title
Chronic Opioid Therapy Statistics: Visit Addressing Pain Management
Description
% of patients on chronic opioids that were seen at a visit addressing pain management in the 6 months prior to Month 17 of the study.
Time Frame
Month 17
Title
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
Description
% of patients on chronic opioids with a chronic pain diagnosis
Time Frame
Baseline
Title
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
Description
% of patients on chronic opioids with a chronic pain diagnosis
Time Frame
Month 17
Title
Chronic Opioid Therapy Statistics: High Risk Patients
Description
% of patients on chronic opioids with MME>50 and benzo
Time Frame
Baseline
Title
Chronic Opioid Therapy Statistics: High Risk Patients
Description
% of patients on chronic opioids with MME>50 and benzo
Time Frame
Month 17
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
For the Practice: Deliver primary care services to older adults. Be located in Oklahoma. Be willing to complete a pre- and post-practice characteristic and building blocks of primary care survey. Use an electronic health record.
For Practice Clinicians: Be an MD, DO, PA, or APRN licensed to practice in Oklahoma. Be willing to complete a pre- and post- practice member survey. Be willing to work with the OPHIC external support personnel to use the performance measures.
For Practice Staff: Be employed by the practice. Be willing to complete a pre- and post- practice member survey. Be willing to work with the OPHIC external support personnel to use performance measures to optimize pain management approaches in older adults.
For Practice Patients: Be chronic pain patients aged 60 or older, or may be younger, but vulnerable due to disability, significant functional limitation or social deprivation. Be willing to complete PROMIS-29 surveys, participate in RISE-OK Project activities, and provide feedback on the RISE-OK program.
Exclusion Criteria:
Practices: Does not provide primary care. Provides only urgent care and does not provide continuity of care or long-term follow-up care. Does not use an electronic health record.
Clinicians: Do not provide primary care with continuity and chronic care follow-up. Planning to leave practice within the next 12 months, including if the clinician is planning to retire within the next 12 months.
Practice Staff: Under 18 years of age.
Patients: Not older adult chronic pain patients.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Timothy VanWagoner, PhD
Phone
(405) 271-3480
Email
Timothy-VanWagoner@ouhsc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Juell Homco, PhD, MPH
Phone
(918) 660-3808
Email
juell-homco@ouhsc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Crawford, MD
Organizational Affiliation
University of Oklahoma
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oklahoma Clinical and Translational Science Institute
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy VanWagoner, PhD
Phone
405-271-3480
Email
timothy-vanwagoner@ouhsc.edu
12. IPD Sharing Statement
Citations:
PubMed Identifier
27959718
Citation
Murthy VH. Ending the Opioid Epidemic - A Call to Action. N Engl J Med. 2016 Dec 22;375(25):2413-2415. doi: 10.1056/NEJMp1612578. Epub 2016 Nov 9. No abstract available.
Results Reference
background
PubMed Identifier
28033313
Citation
Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452. doi: 10.15585/mmwr.mm655051e1.
Results Reference
background
PubMed Identifier
26720857
Citation
Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016 Jan 1;64(50-51):1378-82. doi: 10.15585/mmwr.mm6450a3.
Results Reference
background
PubMed Identifier
30602544
Citation
Levy S. Youth and the Opioid Epidemic. Pediatrics. 2019 Feb;143(2):e20182752. doi: 10.1542/peds.2018-2752. Epub 2019 Jan 2.
Results Reference
background
PubMed Identifier
30384321
Citation
Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend. 2018 Dec 1;193:142-147. doi: 10.1016/j.drugalcdep.2018.10.002. Epub 2018 Oct 18.
Results Reference
background
PubMed Identifier
31044343
Citation
Jones MR, Novitch MB, Sarrafpour S, Ehrhardt KP, Scott BB, Orhurhu V, Viswanath O, Kaye AD, Gill J, Simopoulos TT. Government Legislation in Response to the Opioid Epidemic. Curr Pain Headache Rep. 2019 May 1;23(6):40. doi: 10.1007/s11916-019-0781-1.
Results Reference
background
PubMed Identifier
28564549
Citation
Volkow ND, Collins FS. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017 Jul 27;377(4):391-394. doi: 10.1056/NEJMsr1706626. Epub 2017 May 31. No abstract available.
Results Reference
background
PubMed Identifier
24758595
Citation
Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014 May 29;370(22):2063-6. doi: 10.1056/NEJMp1402780. Epub 2014 Apr 23. No abstract available.
Results Reference
background
PubMed Identifier
28715535
Citation
Liebschutz JM, Xuan Z, Shanahan CW, LaRochelle M, Keosaian J, Beers D, Guara G, O'Connor K, Alford DP, Parker V, Weiss RD, Samet JH, Crosson J, Cushman PA, Lasser KE. Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial. JAMA Intern Med. 2017 Sep 1;177(9):1265-1272. doi: 10.1001/jamainternmed.2017.2468.
Results Reference
background
PubMed Identifier
28062816
Citation
Parchman ML, Von Korff M, Baldwin LM, Stephens M, Ike B, Cromp D, Hsu C, Wagner EH. Primary Care Clinic Re-Design for Prescription Opioid Management. J Am Board Fam Med. 2017 Jan 2;30(1):44-51. doi: 10.3122/jabfm.2017.01.160183.
Results Reference
background
PubMed Identifier
26660909
Citation
West NA, Dart RC. Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiol Drug Saf. 2016 May;25(5):539-44. doi: 10.1002/pds.3934. Epub 2015 Dec 13.
Results Reference
background
PubMed Identifier
20863326
Citation
Buckeridge D, Huang A, Hanley J, Kelome A, Reidel K, Verma A, Winslade N, Tamblyn R. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010 Sep;58(9):1664-70. doi: 10.1111/j.1532-5415.2010.03015.x.
Results Reference
background
PubMed Identifier
25581257
Citation
Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015 Feb 17;162(4):276-86. doi: 10.7326/M14-2559.
Results Reference
background
PubMed Identifier
27586832
Citation
Edwards RR, Dworkin RH, Sullivan MD, Turk DC, Wasan AD. The Role of Psychosocial Processes in the Development and Maintenance of Chronic Pain. J Pain. 2016 Sep;17(9 Suppl):T70-92. doi: 10.1016/j.jpain.2016.01.001.
Results Reference
background
PubMed Identifier
28850370
Citation
Qadeer RA, Shanahan L, Ferro MA. Chronic disruptive pain in emerging adults with and without chronic health conditions and the moderating role of psychiatric disorders: Evidence from a population-based cross-sectional survey in Canada. Scand J Pain. 2017 Oct;17:30-36. doi: 10.1016/j.sjpain.2017.07.009. Epub 2017 Jul 26.
Results Reference
background
PubMed Identifier
26028573
Citation
Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015 Aug;16(8):769-80. doi: 10.1016/j.jpain.2015.05.002. Epub 2015 May 29.
Results Reference
background
PubMed Identifier
28476267
Citation
Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: Results from electronic health records data. J Subst Abuse Treat. 2017 Jun;77:26-30. doi: 10.1016/j.jsat.2017.03.006. Epub 2017 Mar 9.
Results Reference
background
PubMed Identifier
22201184
Citation
Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT, Schwilden H. Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth. 2012 Mar;108(3):491-8. doi: 10.1093/bja/aer395. Epub 2011 Dec 26.
Results Reference
background
PubMed Identifier
19238650
Citation
Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, Olkkola KT. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther. 2008 Oct;84(4):462-7. doi: 10.1038/clpt.2008.64.
Results Reference
background
PubMed Identifier
29223172
Citation
Machado-Duque ME, Castano-Montoya JP, Medina-Morales DA, Castro-Rodriguez A, Gonzalez-Montoya A, Machado-Alba JE. Association between the use of benzodiazepines and opioids with the risk of falls and hip fractures in older adults. Int Psychogeriatr. 2018 Jul;30(7):941-946. doi: 10.1017/S1041610217002745. Epub 2017 Dec 10.
Results Reference
background
PubMed Identifier
29402646
Citation
Seppala LJ, van de Glind EMM, Daams JG, Ploegmakers KJ, de Vries M, Wermelink AMAT, van der Velde N; EUGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am Med Dir Assoc. 2018 Apr;19(4):372.e1-372.e8. doi: 10.1016/j.jamda.2017.12.099. Epub 2018 Mar 2.
Results Reference
background
PubMed Identifier
28467623
Citation
Gerlach LB, Olfson M, Kales HC, Maust DT. Opioids and Other Central Nervous System-Active Polypharmacy in Older Adults in the United States. J Am Geriatr Soc. 2017 Sep;65(9):2052-2056. doi: 10.1111/jgs.14930. Epub 2017 May 3.
Results Reference
background
PubMed Identifier
20642732
Citation
Reid MC, Henderson CR Jr, Papaleontiou M, Amanfo L, Olkhovskaya Y, Moore AA, Parikh SS, Turner BJ. Characteristics of older adults receiving opioids in primary care: treatment duration and outcomes. Pain Med. 2010 Jul;11(7):1063-71. doi: 10.1111/j.1526-4637.2010.00883.x.
Results Reference
background
PubMed Identifier
12418941
Citation
Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002 Nov 11;162(20):2269-76. doi: 10.1001/archinte.162.20.2269.
Results Reference
background
PubMed Identifier
14597458
Citation
Wenger NS, Solomon DH, Roth CP, MacLean CH, Saliba D, Kamberg CJ, Rubenstein LZ, Young RT, Sloss EM, Louie R, Adams J, Chang JT, Venus PJ, Schnelle JF, Shekelle PG. The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med. 2003 Nov 4;139(9):740-7. doi: 10.7326/0003-4819-139-9-200311040-00008.
Results Reference
background
PubMed Identifier
27488204
Citation
Le Roux C, Tang Y, Drexler K. Alcohol and Opioid Use Disorder in Older Adults: Neglected and Treatable Illnesses. Curr Psychiatry Rep. 2016 Sep;18(9):87. doi: 10.1007/s11920-016-0718-x.
Results Reference
background
PubMed Identifier
27426210
Citation
Beaudoin FL, Merchant RC, Clark MA. Prevalence and Detection of Prescription Opioid Misuse and Prescription Opioid Use Disorder Among Emergency Department Patients 50 Years of Age and Older: Performance of the Prescription Drug Use Questionnaire, Patient Version. Am J Geriatr Psychiatry. 2016 Aug;24(8):627-636. doi: 10.1016/j.jagp.2016.03.010. Epub 2016 Apr 1.
Results Reference
background
PubMed Identifier
27567185
Citation
Maree RD, Marcum ZA, Saghafi E, Weiner DK, Karp JF. A Systematic Review of Opioid and Benzodiazepine Misuse in Older Adults. Am J Geriatr Psychiatry. 2016 Nov;24(11):949-963. doi: 10.1016/j.jagp.2016.06.003. Epub 2016 Jun 7.
Results Reference
background
PubMed Identifier
30633773
Citation
Oh G, Abner EL, Fardo DW, Freeman PR, Moga DC. Patterns and predictors of chronic opioid use in older adults: A retrospective cohort study. PLoS One. 2019 Jan 11;14(1):e0210341. doi: 10.1371/journal.pone.0210341. eCollection 2019.
Results Reference
background
PubMed Identifier
30948577
Citation
Kastner M, Hayden L, Wong G, Lai Y, Makarski J, Treister V, Chan J, Lee JH, Ivers NM, Holroyd-Leduc J, Straus SE. Underlying mechanisms of complex interventions addressing the care of older adults with multimorbidity: a realist review. BMJ Open. 2019 Apr 3;9(4):e025009. doi: 10.1136/bmjopen-2018-025009.
Results Reference
background
PubMed Identifier
28367382
Citation
Mold J. Goal-Directed Health Care: Redefining Health and Health Care in the Era of Value-Based Care. Cureus. 2017 Feb 21;9(2):e1043. doi: 10.7759/cureus.1043.
Results Reference
background
PubMed Identifier
29531108
Citation
Nagykaldi ZJ, Tange H, De Maeseneer J. Moving From Problem-Oriented to Goal-Directed Health Records. Ann Fam Med. 2018 Mar;16(2):155-159. doi: 10.1370/afm.2180.
Results Reference
background
PubMed Identifier
27184992
Citation
Purkaple BA, Mold JW, Chen S. Encouraging Patient-Centered Care by Including Quality-of-Life Questions on Pre-Encounter Forms. Ann Fam Med. 2016 May;14(3):221-6. doi: 10.1370/afm.1905.
Results Reference
background
PubMed Identifier
22375966
Citation
Reuben DB, Tinetti ME. Goal-oriented patient care--an alternative health outcomes paradigm. N Engl J Med. 2012 Mar 1;366(9):777-9. doi: 10.1056/NEJMp1113631. No abstract available.
Results Reference
background
PubMed Identifier
30882888
Citation
Reuben DB, Jennings LA. Putting Goal-Oriented Patient Care Into Practice. J Am Geriatr Soc. 2019 Jul;67(7):1342-1344. doi: 10.1111/jgs.15885. Epub 2019 Mar 18.
Results Reference
background
PubMed Identifier
31361866
Citation
Goga JK, Michaels A, Zisselman M, DePaolo A, Khushalani S, Walters JK, Poloway A, Roca R, Kopp M. Reducing opioid use for chronic pain in older adults. Am J Health Syst Pharm. 2019 Apr 8;76(8):554-559. doi: 10.1093/ajhp/zxz025.
Results Reference
background
PubMed Identifier
18612060
Citation
Mold JW, Aspy CA, Nagykaldi Z; Oklahoma Physicians Resource/Research Network. Implementation of evidence-based preventive services delivery processes in primary care: an Oklahoma Physicians Resource/Research Network (OKPRN) study. J Am Board Fam Med. 2008 Jul-Aug;21(4):334-44. doi: 10.3122/jabfm.2008.04.080006.
Results Reference
background
PubMed Identifier
24423078
Citation
McCormack L, Sheridan S, Lewis M, Boudewyns V, Melvin CL, Kistler C, Lux LJ, Cullen K, Lohr KN. Communication and dissemination strategies to facilitate the use of health-related evidence. Evid Rep Technol Assess (Full Rep). 2013 Nov;(213):1-520. doi: 10.23970/ahrqepcerta213.
Results Reference
background
PubMed Identifier
30069724
Citation
Mathis SM, Hagemeier N, Hagaman A, Dreyzehner J, Pack RP. A Dissemination and Implementation Science Approach to the Epidemic of Opioid Use Disorder in the United States. Curr HIV/AIDS Rep. 2018 Oct;15(5):359-370. doi: 10.1007/s11904-018-0409-9.
Results Reference
background
PubMed Identifier
28353501
Citation
Dwyer JW, Contreras D, Eschbach CL, Tiret H, Newkirk C, Carter E, Cronk L. Cooperative Extension as a Framework for Health Extension: The Michigan State University Model. Acad Med. 2017 Oct;92(10):1416-1420. doi: 10.1097/ACM.0000000000001640.
Results Reference
background
PubMed Identifier
19549977
Citation
Grumbach K, Mold JW. A health care cooperative extension service: transforming primary care and community health. JAMA. 2009 Jun 24;301(24):2589-91. doi: 10.1001/jama.2009.923. No abstract available.
Results Reference
background
PubMed Identifier
28893819
Citation
Kaufman A, Boren J, Koukel S, Ronquillo F, Davies C, Nkouaga C. Agriculture and Health Sectors Collaborate in Addressing Population Health. Ann Fam Med. 2017 Sep;15(5):475-480. doi: 10.1370/afm.2087.
Results Reference
background
PubMed Identifier
23508605
Citation
Phillips RL Jr, Kaufman A, Mold JW, Grumbach K, Vetter-Smith M, Berry A, Burke BT. The primary care extension program: a catalyst for change. Ann Fam Med. 2013 Mar-Apr;11(2):173-8. doi: 10.1370/afm.1495.
Results Reference
background
PubMed Identifier
29866120
Citation
Chou AF, Homco JB, Nagykaldi Z, Mold JW, Daniel Duffy F, Crawford S, Stoner JA. Disseminating, implementing, and evaluating patient-centered outcomes to improve cardiovascular care using a stepped-wedge design: healthy hearts for Oklahoma. BMC Health Serv Res. 2018 Jun 4;18(1):404. doi: 10.1186/s12913-018-3189-4.
Results Reference
background
PubMed Identifier
24615313
Citation
Bodenheimer T, Ghorob A, Willard-Grace R, Grumbach K. The 10 building blocks of high-performing primary care. Ann Fam Med. 2014 Mar-Apr;12(2):166-71. doi: 10.1370/afm.1616.
Results Reference
background
PubMed Identifier
2912463
Citation
Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum. 1989 Jan;32(1):37-44. doi: 10.1002/anr.1780320107.
Results Reference
background
PubMed Identifier
19418100
Citation
Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, Asch SM, Kroenke K. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009 Jun;24(6):733-8. doi: 10.1007/s11606-009-0981-1. Epub 2009 May 6.
Results Reference
background
Citation
Pergolizzi JJV, LeQuang JA. Aging High: Opioid Use Disorder in the Elderly Population. OBM Geriatrics. 2018;3(2):1-. doi: 10.21926/obm.geriatr.1902047.
Results Reference
background
PubMed Identifier
16951300
Citation
Nagykaldi Z, Mold JW, Robinson A, Niebauer L, Ford A. Practice facilitators and practice-based research networks. J Am Board Fam Med. 2006 Sep-Oct;19(5):506-10. doi: 10.3122/jabfm.19.5.506.
Results Reference
background
PubMed Identifier
24851288
Citation
Committee on Integrating Primary Care and Public Health; Board on Population Health and Public Health Practice; Institute of Medicine. Primary Care and Public Health: Exploring Integration to Improve Population Health. Washington (DC): National Academies Press (US); 2012 Mar 28. Available from http://www.ncbi.nlm.nih.gov/books/NBK201594/
Results Reference
background
Citation
Breslow NE, Clayton DG. Approximate Inference in Generalized Linear Mixed Models. Journal of the American Statistical Association. 1993;88(421). doi: 10.2307/2290687.
Results Reference
background
Citation
McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed: Chapman & Hall/CRC Press; 1989.
Results Reference
background
Citation
Pinheiro JC, Chao EC. Efficient Laplacian and Adaptive Gaussian Quadrature Algorithms for Multilevel Generalized Linear Mixed Models. Journal of Computational and Graphical Statistics. 2012;15(1):58-81. doi: 10.1198/106186006x96962.
Results Reference
background
Links:
URL
https://www.cdc.gov/drugoverdose/rxrate-maps/state2017.html
Description
U.S. Opioid Prescribing Rate Maps [Internet] 2017
URL
https://wonder.cdc.gov/
Description
CDC WONDER Database [Internet] 2017
URL
https://data.cms.gov/tools
Description
Medicare Part D Opioid Prescribing Mapping Tool [Internet] 2017
Learn more about this trial
Pain and Opioid Management in Older Adults
We'll reach out to this number within 24 hrs